Fundamental Analysis of ONCONETIX INC(NASDAQ:ONCO) stock

Fundamental Rating

Overall ONCO gets a fundamental rating of 0 out of 10. We evaluated ONCO against 571 industry peers in the Biotechnology industry. ONCO has a bad profitability rating. Also its financial health evaluation is rather negative. ONCO has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

ONCO had negative earnings in the past year.

ONCO had a negative operating cash flow in the past year.

ONCO had negative earnings in each of the past 5 years.

ONCO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of ONCO (-89.34%) is worse than 71.96% of its industry peers.

ONCO's Return On Equity of -186.90% is on the low side compared to the rest of the industry. ONCO is outperformed by 67.72% of its industry peers.

		Industry Rank	Sector Rank
ROA	-89.34%
ROE	-186.9%
ROIC	N/A

ROA(3y)-75.1%

ROA(5y)-57.66%

ROE(3y)-134.27%

ROE(5y)-93.36%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONCO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ONCO does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ONCO has less shares outstanding

Compared to 1 year ago, ONCO has a worse debt to assets ratio.

2.2 Solvency

ONCO has an Altman-Z score of -3.15. This is a bad value and indicates that ONCO is not financially healthy and even has some risk of bankruptcy.

ONCO's Altman-Z score of -3.15 is in line compared to the rest of the industry. ONCO outperforms 47.44% of its industry peers.

ONCO has a Debt/Equity ratio of 0.53. This is a neutral value indicating ONCO is somewhat dependend on debt financing.

With a Debt to Equity ratio value of 0.53, ONCO is not doing good in the industry: 73.90% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.53
Debt/FCF	N/A
Altman-Z	-3.15

ROIC/WACCN/A

WACC9.59%

2.3 Liquidity

A Current Ratio of 0.10 indicates that ONCO may have some problems paying its short term obligations.

With a Current ratio value of 0.10, ONCO is not doing good in the industry: 98.24% of the companies in the same industry are doing better.

ONCO has a Quick Ratio of 0.10. This is a bad value and indicates that ONCO is not financially healthy enough and could expect problems in meeting its short term obligations.

ONCO's Quick ratio of 0.09 is on the low side compared to the rest of the industry. ONCO is outperformed by 98.24% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.1
Quick Ratio	0.09

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ONCO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -8511.85%.

EPS 1Y (TTM)-8511.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-5895.86%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ONCO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -14.13% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-11.84%

EPS Next 2Y-14.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONCO. In the last year negative earnings were reported.

Also next year ONCO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ONCO's earnings are expected to decrease with -14.13% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-14.13%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ONCO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ONCONETIX INC

NASDAQ:ONCO (11/29/2024, 4:40:37 PM)

After market: 0.718 +0.03 (+4.06%)

0.69

+0.03 (+4.23%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap5.72M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-89.34%
ROE	-186.9%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0.53
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.1
Quick Ratio	0.09
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-8511.85%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-11.84%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ONCONETIX INC (ONCO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens